Modeling strategies for pharmaceutical blend monitoring and end-point determination by near-infrared spectroscopy

被引:27
作者
Igne, Benoit [1 ]
de Juan, Anna [2 ]
Jaumot, Joaquirn [3 ]
Lallemand, Jordane [4 ]
Preys, Sebastien [4 ]
Drennen, James K. [1 ]
Anderson, Carl A. [1 ]
机构
[1] Duquesne Univ, Duquesne Ctr Pharmaceut Technol, Pittsburgh, PA 15282 USA
[2] Univ Barcelona, Dept Analyt Chem, E-08028 Barcelona, Spain
[3] IDAEA CSIC, Barcelona 08034, Spain
[4] Ondaly, F-34730 Prades Le Lez, France
关键词
Pharmaceutical blend; End-point detection; Multivariate curve resolution; Prototype; Near-infrared spectroscopy; Chemometrics; MULTIVARIATE CURVE RESOLUTION; PART II; QUANTITATIVE-ANALYSIS; AUTOMATED-SYSTEM; MCR-ALS; POWDER; HOMOGENEITY; TOOL;
D O I
10.1016/j.ijpharm.2014.06.061
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The implementation of a blend monitoring and control method based on a process analytical technology such as near infrared spectroscopy requires the selection and optimization of numerous criteria that will affect the monitoring outputs and expected blend end-point. Using a five component formulation, the present article contrasts the modeling strategies and end-point determination of a traditional quantitative method based on the prediction of the blend parameters employing partial least-squares regression with a qualitative strategy based on principal component analysis and Hotelling's T-2 and residual distance to the model, called Prototype. The possibility to monitor and control blend homogeneity with multivariate curve resolution was also assessed. The implementation of the above methods in the presence of designed experiments (with variation of the amount of active ingredient and excipients) and with normal operating condition samples (nominal concentrations of the active ingredient and excipients) was tested. The impact of criteria used to stop the blends (related to precision and/or accuracy) was assessed. Results demonstrated that while all methods showed similarities in their outputs, some approaches were preferred for decision making. The selectivity of regression based methods was also contrasted with the capacity of qualitative methods to determine the homogeneity of the entire formulation. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:219 / 231
页数:13
相关论文
共 50 条
[41]  
Tauler R, 2009, COMPREHENSIVE CHEMOMETRICS: CHEMICAL AND BIOCHEMICAL DATA ANALYSIS, VOLS 1-4, pA473
[42]   MULTIVARIATE CONTROL CHARTS FOR INDIVIDUAL OBSERVATIONS [J].
TRACY, ND ;
YOUNG, JC ;
MASON, RL .
JOURNAL OF QUALITY TECHNOLOGY, 1992, 24 (02) :88-95
[43]  
U.S. Department of Health and Human Services, 2004, GUID IND PAT A FRAM
[44]  
United States Pharmacopeia-National Formulary, 1999, US PHARM NAT FORM OF
[45]   Powder sampling [J].
Venables, HJ ;
Wells, JI .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (02) :107-117
[46]   Near-infrared spectroscopic characterization of pharmaceutical powder blends [J].
Wargo, DJ ;
Drennen, JK .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1996, 14 (11) :1415-1423
[47]   INTERACTIVE SELF-MODELING MIXTURE ANALYSIS [J].
WINDIG, W ;
GUILMENT, J .
ANALYTICAL CHEMISTRY, 1991, 63 (14) :1425-1432
[48]   PRINCIPAL COMPONENT ANALYSIS [J].
WOLD, S ;
ESBENSEN, K ;
GELADI, P .
CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 1987, 2 (1-3) :37-52
[49]   PLS-regression:: a basic tool of chemometrics [J].
Wold, S ;
Sjöström, M ;
Eriksson, L .
CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 2001, 58 (02) :109-130
[50]   Quality-By-Design (QbD): An Integrated Approach for Evaluation of Powder Blending Process Kinetics and Determination of Powder Blending End-point [J].
Wu, Huiquan ;
Khan, Mansoor A. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (08) :2784-2798